Bacteriological and clinical studies on FK037

We performed bacteriological and clinical studies on FK037, a new parenteral cephalosporin antibiotic, with the following results. 1) Antimicrobial activity The MIC₉₀ of FK037 against various clinical isolates (10 species, 238 strains) was as follows: 3.13 μg/ml against methicillin-sensitive Staphylococcus aureus, 50 μg/ml against methicillin-resistant S. aureus (MRSA), >100 μg/ml against Enterococcus faecalis, 0.10μg/ml against Escherichia coli, ≦ 0.05 μg/ml against Klebsiella pneumoniae, 3.13 μg/ml against Enterobacter cloacae, 1.56 μg/ml against Enterobacter aerogenes, 3.13 μg/ml against Citrobacter freundii, ≦0.05 μg/ml against Proteus mirabilis, 0.10 μg/ml against Proteus vulgaris, 25μg/ml against Pseudomonas aeruginosa. Its activity against these bacterial species including MRSA was more potent than that of control drugs; ceftazidime (CAZ), flomoxef (FM0X), ceftizoxime (CZX) and cefotiam (CTM). The activity against P. aeruginosa was almost as potent as that of CAZ. The activity against E. faecalis was less active as well as that of the control drugs. 2) Clinical efficacy Four patients with pneumonia were treated with FK037 at daily doses of 1.0 or 4.0 g for 7~14 days. Clinical response was excellent in 3 patients and good in 1. No adverse reactions or abnormal laboratory findings were observed.